Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/new-chemotherapies-in-breast-cancer-QDE7gjPl6Q
References (36)
-
S. Dent, J. Fraser, N. Graham, M. Campbell, S. Hopkins, G. Dranitsaris (2013)
Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.Current oncology, 20 1
-
B Leyland-Jones DJ Slamon (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N. Engl. J. Med., 344
-
J Finek M Aapro (2012)
Oral vinorelbine in metastatic breast cancer: a review of current clinical trial resultsCancer Treat Rev, 38
-
M. O'brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D. Kieback, P. Tomczak, S. Ackland, F. Orlandi, L. Mellars, L. Alland, C. Tendler (2004)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 15 3
-
S. Isakoff, J. Baselga (2011)
Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 4
-
M. Coombes, Emma Ph.D., Lorna Ph.D., Robert M.Phil., Ph.D Jassem, Thierry Ph.D., Stephen M.D., Isabel M.D., M. Bertelli, Olaf M.D., Alan Ph.D., Emilio M.D., David M.D., M. Coleman, Lesley M.D., D.Phil, M. Mickiewicz, D.M.Sc Andersen, Per Lønning, Giorgio Ph.D., Alan Ph.D., Nick M.D., M.Sc Snowdon, Ph.D Carpentieri, M. Massimini, M.Sc Bliss (1977)
THE NEW ENGLAND JOURNAL OF MEDICINEThe Lancet, 309
-
I. Krop, Sung-Bae Kim, A. González-Martín, P. LoRusso, J. Ferrero, M. Smitt, R. Yu, A. Leung, H. Wildiers (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.The Lancet. Oncology, 15 7
-
S. Tolaney, W. Barry, C. Dang, D. Yardley, B. Moy, P. Marcom, K. Albain, H. Rugo, M. Ellis, I. Shapira, A. Wolff, L. Carey, B. Overmoyer, A. Partridge, Hao Guo, C. Hudis, I. Krop, H. Burstein, E. Winer (2015)
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.The New England journal of medicine, 372 2
-
E. Perez, C. Barrios, W. Eiermann, M. Toi, Y. Im, P. Conte, Miguel Martín, T. Pieńkowski, X. Pivot, H. Burris, J. Petersen, S. Stanzel, A. Strasak, M. Patre, P. Ellis (2016)
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE StudyJournal of Clinical Oncology, 35
-
S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh, V. Diéras, E. Guardino, L. Fang, Michael Lu, S. Olsen, K. Blackwell (2012)
Trastuzumab emtansine for HER2-positive advanced breast cancer.The New England journal of medicine, 367 19
-
Y. Zong, Jiayi Wu, K. Shen (2017)
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysisOncotarget, 8
-
N. Masuda, Soo-Jung Lee, S. Ohtani, Y. Im, Eun-Sook Lee, I. Yokota, K. Kuroi, S. Im, Byeong-Woo Park, Sung-Bae Kim, Y. Yanagita, S. Ohno, S. Takao, K. Aogi, H. Iwata, Joon Jeong, Aeree Kim, K. Park, H. Sasano, Y. Ohashi, M. Toi (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyThe New England Journal of Medicine, 376
-
G. Hortobagyi (2005)
Present situation and future of genetic profiling for prognosis and treatmentBreast Cancer Research : BCR, 7
-
F. Cabanillas, G. Bodey, M. Burgess, E. Freireich (1979)
Results of a phase II study of maytansine in patients with breast carcinoma and melanoma.Cancer treatment reports, 63 3
-
J. Stump, A. Tufman, S. Reu, F. Berger, Carmen Ballesteros-Merino, M. Neuberger, Zipei Feng, R. Hatz, M. Lindner, R. Sanbom, John Handy, B. Fox, Carlo Bifulco, R. Huber, H. Winter (2016)
32. Deutscher Krebskongress Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ, Berlin, 24.-27. Februar 2016: AbstractsOncology Research and Treatment, 39
-
G. Minckwitz, A. Schneeweiss, S. Loibl, C. Salat, C. Denkert, M. Rezai, J. Blohmer, C. Jackisch, S. Paepke, B. Gerber, D. Zahm, S. Kümmel, H. Eidtmann, P. Klare, J. Huober, S. Costa, H. Tesch, C. Hanusch, J. Hilfrich, F. Khandan, P. Fasching, B. Sinn, K. Engels, K. Mehta, V. Nekljudova, M. Untch (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.The Lancet. Oncology, 15 7
-
D. Yardley, A. Brufsky, R. Coleman, P. Conte, J. Cortés, S. Glück, J. Nabholtz, J. O’Shaughnessy, R. Beck, A. Ko, M. Renschler, D. Barton, N. Harbeck (2015)
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialTrials, 16
-
A. Lohmann, C. Speers, Stephen Chia (2013)
Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia.Current oncology, 20 2
-
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.The New England journal of medicine, 353 16
-
P. Kaufman, A. Awada, C. Twelves, L. Yelle, E. Perez, G. Velikova, M. Olivo, Yi He, C. Dutcus, J. Cortés (2015)
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 33
-
N. Desai, V. Trieu, Z. Yao, Leslie Louie, S. Ci, Andrew Yang, C. Tao, T. De, Bridget Beals, D. Dykes, P. Noker, R. Yao, Elizabeth Labao, M. Hawkins, P. Soon-Shiong (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.Clinical cancer research : an official journal of the American Association for Cancer Research, 12
-
Joong-Gon Shin, H. Cheong, Jason-Y. Kim, L. Kim, C. Han, Ji Kim, H. Kim, Young Kim, M. Chung, S. Han, H. Shin (2013)
Screening of Dihydropyrimidine Dehydrogenase Genetic Variants by Direct Sequencing in Different Ethnic GroupsJournal of Korean Medical Science, 28
-
L. Harris, G. Batist, R. Belt, Douglas Rovira, R. Navari, N. Azarnia, L. Welles, E. Winer (2002)
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinomaCancer, 94
-
W. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, J. O’Shaughnessy (2005)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
-
J O’Shaughnessy J Cortes (2011)
Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet, 377
-
S. Swain, J. Baselga, Sung-Bae Kim, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J. Ferrero, A. Schneeweiss, S. Heeson, E. Clark, G. Ross, M. Benyunes, J. Cortés (2015)
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.The New England journal of medicine, 372 8
-
J. Thigpen (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyYearbook of Medicine, 2011
-
M. Untch, C. Jackisch, A. Schneeweiss, B. Conrad, B. Aktas, C. Denkert, H. Eidtmann, H. Wiebringhaus, S. Kümmel, J. Hilfrich, M. Warm, S. Paepke, M. Just, C. Hanusch, J. Hackmann, J. Blohmer, M. Clemens, S. Darb-Esfahani, W. Schmitt, S. Costa, B. Gerber, K. Engels, V. Nekljudova, S. Loibl, G. Minckwitz (2016)
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.The Lancet. Oncology, 17 3
-
Ying-chun Xu, Hong-Xia Wang, Lei Tang, Yue Ma, Feng-chun Zhang (2013)
A Systematic Review of Vinorelbine for the Treatment of Breast CancerThe Breast Journal, 19
-
E. Perez, A. Awada, J. O’Shaughnessy, H. Rugo, C. Twelves, S. Im, P. Gómez-Pardo, L. Schwartzberg, V. Diéras, D. Yardley, D. Potter, A. Mailliez, A. Moreno-Aspitia, J. Ahn, Carol Zhao, U. Hoch, M. Tagliaferri, A. Hannah, J. Cortés (2015)
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.The Lancet. Oncology, 16 15
-
Meiyuan Xing, Feifei Yan, Sufen Yu, P. Shen (2015)
Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled TrialsPLoS ONE, 10
-
C. Geyer, J. O’Shaughnessy, M. Untch, W. Sikov, H. Rugo, M. McKee, J. Huober, M. Golshan, V. Giranda, G. Minckwitz, D. Maag, D. Sullivan, N. Wolmark, K. McIntyre, J. Lorenzo, O. Filho, P. Rastogi, W. Symmans, Xuan Liu, S. Loibl (2017)
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).Journal of Clinical Oncology, 35
-
M. Telli, K. Timms, J. Reid, B. Hennessy, G. Mills, K. Jensen, Z. Szallasi, W. Barry, E. Winer, N. Tung, S. Isakoff, P. Ryan, April Greene-Colozzi, A. Gutin, Zaina Sangale, D. Iliev, C. Neff, V. Abkevich, Joshua Jones, J. Lanchbury, A. Hartman, J. Garber, J. Ford, D. Silver, A. Richardson (2016)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerClinical Cancer Research, 22
-
L. Gianni, M. Mansutti, A. Antón, L. Calvo, G. Bisagni, B. Bermejo, V. Semiglazov, M. Thill, J. Chacón, A. Chan, S. Morales, I. Álvarez, A. Plazaola, M. Zambetti, A. Redfern, C. Dittrich, R. Dent, D. Magazzù, P. Valagussa, I. Tusquets (2016)
ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.Journal of Clinical Oncology, 34
-
H Kreipe (2015)
Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial -
S. Swain, F. Whaley, M. Ewer (2003)
Congestive heart failure in patients treated with doxorubicinCancer, 97
- Publisher
- Springer Journals
- Copyright
- 2017 Springer-Verlag GmbH Austria
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-017-0348-y
- Publisher site
- See Article on Publisher Site
Abstract
Summary In the era of targeted therapies and immunotherapy for cancer, the focus in breast cancer (BC) research has shifted away from classical chemotherapy. Many BC patients, however, still need chemotherapy and thus benefit from the development of new chemotherapeutic agents or regimens. In the past decade, the approval of eribulin and trastuzumab emtansine (T-DM1) have been important advances in this regard. Improved ways of delivery of paclitaxel, anthracyclines, and vinorelbine have also had a considerable clinical impact. Finally, optimizing the use of well-known drugs, such as carboplatin, capecitabine, or adjuvant chemoimmunotherapy in low-risk early BC, has brought about progress in the field of chemo(immuno)therapy.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 1, 2017